Bioasis Technologies Inc. V.BTI

RE:RE:RE:RE:RE:RE:Accountability for Low-value Deals

[G1945V]

chrispi wrote:

prophetoffact wrote: So, total it all up and it could be a well over $600 million deal and BTI doesn't have to invest in it anymore and can license other companies and pursue its own Parkinson's drug.

prophetoffact wrote: Assuming the Levodopa revenue is right and BTI was entitled to a 5% royalty BTI could receive C$91 million in milestone payments and up to or more than C$170 million in annual royalty payments if the drug reached similar revenue levels to Levodopa.  


"Levodopa/Carbidopa segment revenue was around USD 2.64 billion in 2020."

"Parkinson’s Disease Therapeutic Market size is set to surpass USD 8 billion by 2027, according to a new research report by Global Market Insights Inc."

Parkinson’s Disease Therapeutic Market worth over $8bn by 2027 (gminsights.com)
 

 

Well I have to side with prophetoffact on this one. LIke he says, total it all up and it could be a well over $600 million deal and BTI doesn't have to invest in it anymore and can license other companies and pursue its own Parkinson's drug.
That's the key, this is a non-exclusive deal in the Parkinson's space. Who cares if it isn't the best deal that Bioasis has every publicly announced, we don't even know that b/c all the details like upfront $ weren't stated. It doesn't matter as it is a one off with non-exclusivity so it doesn't imply that every PD drug maker is going to get the same terms or anything close.

And about that "not including the upfront $" in the PR, given that the market anticipates other deals coming, why release specific terms for this deal that could influence other active deals. What terms Neuramedy got are not available for others - one off, special situation, and not a bad deal as prophetoffacts stated with $600+ possible and not a penny spent by Bioasis or exclusion from us or others entering the Parkinson's space.

Crispi : What comes to mind going in that direction, is what JD stated a few posts back. Bioasis to become not too palatable as an acquisition if that's what we want as the end game with this investment.

"And there is an increasing problem with Bioasis. With more and more licensing deals, collaborations and partnerships that Bioasis enters, the less attractive Bioasis may be too large suitors. With so many partners, acquiring pharma may find itself in partnership with its competitors. The many partners could have business focuses or even overall corporate size that may cause Bioasis to become not too palatable as an acquisition."

G1945V